Topic: tyrosine kinase inhibitors
The data tee Seattle Genetics up to file for FDA approval of a TKI inhibitor it paid $614 million to acquire last year.
Principia has started a phase 3 program for its BTK inhibitor in the autoimmune disease pemphigus after hitting the target in a midstage trial.
BMS’ tyrosine kinase 2 inhibitor checked off a phase 2 psoriasis trial, showing high levels of skin clearance after three months of daily treatment.
The FDA cleared Roche’s cobas EGFR test for use as a companion diagnostic for AstraZeneca’s Iressa in first-line non-small cell lung cancer.
Gilead’s senior director of clinical research, Adrian Ray, has moved to Nimbus Therapeutics to become its senior vice president of discovery biology.
X4 Pharma said the 23% objective response rate was "encouraging" as it was observed in third-line patients, a group whose response rate hovers around 10%.
The past week ushered in discoveries that could inspire new treatments for Lyme disease and several cancers.
The MET-TKI triggered partial responses in a significant minority of NSCLC patients who had progressed after treatment with an EGFR-TKI.
TP Therapeutics has the funds on hand to take its drug for resistant cancer through the next stages of clinical development after raising $45 million in a series C financing.
Astellas has halted a phase 3 trial of ASP8273 in NSCLC and scrapped plans to start other development programs targeting the indication.